Misoprostol for postpartum hemorrhage: Advocacy, Approval, Access
(May 8, 2013) Misoprostol is a safe and effective medicine for preventing and treating postpartum hemorrhage (PPH), the leading cause of maternal death. While it is practical for use both at health facilities and in home births, misoprostol is not widely available or accessible in many countries.
In a global webinar hosted by FCI in partnership with Gynuity Health Projects, PSI, and PATH, presenters shared advocacy success stories on expanding access to misoprostol for treatment and prevention of PPH. Experts from Tanzania, Uganda and Somaliland shared effective advocacy strategies for achieving policy change and ensuring women’s access to this essential medicine.
The webinar, Misoprostol for Postpartum Hemorrhage: Advocacy, Approval, Access, was moderated by Amy Boldosser-Boesch, FCI's Director of Global Advocacy, and included interactive slide presentations (PDF, 1.5 MB) by:
- Dr. Nuriye Nalan Sahin-Hodoglugil, Associate Medical Director with VSI Innovations in Tanzania, presenting on "Introducing misoprostol for postpartum hemorrhage in Tanzania
From Policy to Practice"
- Dr. Moses Muwonge, a consultant from Uganda, on "Introducing Misoprostol for PPH: the Uganda Experience"
- Manuela Tolmino, Health Services Technical Advisor with PSI Somaliland, on "Increasing Access to Misoprostol in Somaliland"
Listen to a full audio recording of the presentation here (MP3, 8.4 MB).